Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for previously treated oesophageal or gastro-oesophageal junction cancer.
Appraisal suspended
|
Status
|
Suspended
|
| Process |
STA 2018
|
| ID number |
1357
|
Email enquiries
Consultees
| Companies sponsors |
Merck Sharp & Dohme (pembrolizumab) |
| Others |
Department for Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
Commentators
| Comparator companies |
Accord Healthcare (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
| |
Actavis UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
| |
Celgene (paclitaxel) (not signed confidentiality agreement) |
| |
Hospira UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
| |
Medac GmbH (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
| |
Pfizer Ltd (irinotecan) (not signed confidentiality agreement) |
| |
Sanofi (docetaxel) (not signed confidentiality agreement) |
| |
Seacross Pharmaceuticals (docetaxel, irinotecan) (not signed confidentiality agreement) |
| |
Shire Pharmaceuticals (irinotecan) (not signed confidentiality agreement) |
| General commentators |
All Wales Therapeutic and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Cancer Research Institute |
|
Date
|
Update
|
|
16 September 2019
|
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
|
11 April 2019
|
Suspended, Appraisal suspended |
|
07 March 2019
|
Invitation to participate |
|
04 April 2018 - 02 May 2018
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
|
01 March 2017
|
In progress, DH Referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance